1. Signaling Pathways
  2. GPCR/G Protein
  3. Bradykinin Receptor
  4. Bradykinin Receptor Antagonist

Bradykinin Receptor Antagonist

Bradykinin Receptor Antagonists (27):

Cat. No. Product Name Effect Purity
  • HY-17446
    Icatibant
    Antagonist 99.63%
    Icatibant (HOE-140) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively.
  • HY-108896
    Icatibant acetate
    Antagonist 99.65%
    Icatibant acetate (HOE-140 acetate) is a potent and specific peptide antagonist of bradykinin B2 receptor with an IC50 and Ki of 1.07 nM and 0.798 nM respectively.
  • HY-15039
    SSR240612
    Antagonist 99.51%
    SSR240612 is a potent, and orally active specific non-peptide bradykinin B1 receptor antagonist, with Kis of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells expressing human B1 receptor, respectively.
  • HY-121156A
    Anatibant hydrochloride
    Antagonist
    Anatibant (LF 16-0687; XY-2405) hydrochloride is a selective non-peptide bradykinin B2 receptor antagonist. Anatibant hydrochloride binds to the human, rat and guinea-pig recombinant B2 receptor with Ki values of 0.67 nM, 1.74 nM and 1.37 nM, respectively. Anatibant hydrochloride crosses the blood-brain barrier (BBB). Anatibant hydrochloride can be used in research on brain damage diseases.
  • HY-147273
    Fulimetibant
    Antagonist 99.74%
    Fulimetibant is a bradykinin receptor antagonist.
  • HY-103290
    R715
    Antagonist 99.45%
    R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin(HY-13753)-diabetic mice.
  • HY-103289
    MEN 11270
    Antagonist 99.15%
    MEN 11270, a cyclic decapeptide, is a B2 kinin receptor antagonist. MEN 11270 bound with high-affinity to the B2 kinin receptor constitutively expressed by WI38 human fibroblasts, inhibiting 3H-bradykinin (BK) with a pKi value of 10.3.
  • HY-15043
    ELN-441958
    Antagonist 99.51%
    ELN-441958 is a potent, neutral, competitive and selective bradykinin B1 receptor antagonist with a Ki of 0.26 nM against native human bradykinin B1 receptor. ELN-441958 has high oral bioavailability, and has low CNS exposure in the mouse.
  • HY-P4676
    Lys-(Des-Arg9,Leu8)-Bradykinin
    Antagonist 98.23%
    Lys-(Des-Arg9,Leu8)-Bradykinin is a bradykinin B1 receptor antagonist.
  • HY-121156
    Anatibant
    Antagonist
    Anatibant (LF 16-0687; XY-2405) is a selective non-peptide bradykinin B2 receptor antagonist. Anatibant binds to the human, rat and guinea-pig recombinant B2 receptor with Ki values of 0.67 nM, 1.74 nM and 1.37 nM, respectively. Anatibant crosses the blood-brain barrier (BBB). Anatibant can be used in research on brain damage diseases.
  • HY-106277
    Fasitibant free base
    Antagonist
    Fasitibant (free base) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant (free base) has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis.
  • HY-P3232
    B 9430
    Antagonist
    B 9430 is a potent bradykinin B1/B2 receptor antagonist.
  • HY-106277A
    Fasitibant chloride hydrochloride
    Antagonist
    Fasitibant chloride hydrochloride (MEN16132) is a potent, selective, high affinity, and long-lasting nonpeptide bradykinin B2 (BK2) receptor antagonist. Fasitibant chloride hydrochloride has proinflammatory effects and can be used for the research of osteoarthritis and rheumatoid arthritis.
  • HY-100301
    FR167344 free base
    Antagonist
    FR167344 free base is an orally active, nonpeptide bradykinin receptor B2 antagonist. FR167344 free base shows a high affinity binding to the B2 receptor with an IC50 value of 65 nM and no binding affinity for the B1 receptor.
  • HY-P1694
    B4148
    Antagonist
    B4148 is a selective competitive bradykinin (BK) antagonist that significantly inhibits BK-induced hypotension in rats. In a rat model of endotoxin shock induced by Escherichia coli lipopolysaccharide, B4148 significantly attenuated the decrease in mean arterial blood pressure compared with the control group.
  • HY-P2109
    JMV-1645
    Antagonist
    JMV-1645 is a potent and selective B1 bradykinin receptor antagonist with a Ki value of 0.023 nM on the human cloned B1 receptor. JMV-1645 can be utilized in trauma and infection research.
  • HY-158262
    Bradykinin B1 receptor antagonist 1
    Antagonist
    Bradykinin B1 receptor antagonist 1 (compound 6B) is a potent and cross the blood-brain barrier bradykinin B1 antagonist. Bradykinin B1 receptor antagonist 1 has the potential for the research of pain.
  • HY-100827
    Safotibant
    Antagonist
    Safotibant (LF22-0542) is a selective antagonist for kinin B1 receptor (BKB1R), with Ki of 0.35 and 6.5 nM, for human and mouse BKB1R, respectively. Safotibant exhibits analgesic and anti-inflammatory property in mice model.
  • HY-14886
    Fasitibant chloride
    Antagonist
    Fasitibant chloride (MEN16132 free base) is a potent and selective nonpeptide bradykinin B2 receptor (B2R) antagonist. Fasitibant chloride reduces joint pain and diminishes joint oedema in Carrageenan-induced arthritis rat model.
  • HY-P1721
    NPC 17731
    Antagonist
    NPC 17731 is a new bradykinin (BK) receptor antagonist. NPC 17731 antagonized both the contractile and relaxant responses caused by BK in longitudinal smooth muscle with IC50 of 23 and 29 nM, respectively.